Program Code: SCF-DBI-PCICU-PHARM-0001**
Operational Window: Admission → Stabilization → Recovery → Longitudinal Management
Primary Objective: Optimize cardiovascular pharmacotherapy while preserving neurodevelopment, endothelial integrity, immune adaptation, myocardial recovery, and long-term biologic intelligence.
SECTION 13.1
CLINICAL POSITIONING
Traditional Cardiac Pharmacology Model
Focuses on:
Drug efficacy
Hemodynamic targets
Therapeutic drug levels
Adverse event prevention
SCF-DBI Pharmacology Model
Every pharmacologic intervention is evaluated according to its effects upon:
Cardiac Intelligence
Endothelial Intelligence
Neurodevelopment
Recovery Biology
Immune Adaptation
Functional Recovery
Core Principle
The optimal cardiovascular therapy maximizes adaptive recovery while minimizing biologic intelligence disruption.
SECTION 13.2
RHENOVA PRECISION CARDIOVASCULAR PHARMACOTHERAPY PLATFORM
Strategic Objective
Integrate pharmacologic decisions directly into biological intelligence surveillance.
Core Domains
Domain 1
Hemodynamic Pharmacology
Domain 2
Electrophysiologic Pharmacology
Domain 3
Endothelial Pharmacology
Domain 4
Immunopharmacology
Domain 5
Recovery Pharmacology
Domain 6
Developmental Pharmacology
Primary Output
Cardiovascular Pharmacologic Adaptation Index (CPAI)
SECTION 13.3
CARDIAC PHARMACOLOGY INTELLIGENCE SURVEILLANCE SYSTEM
Purpose
Measure cumulative pharmacologic burden.
Domain A
Therapeutic Effectiveness
Domain B
Hemodynamic Impact
Domain C
Developmental Impact
Domain D
Recovery Impact
Domain E
Immune Impact
Output
Cardiovascular Drug Intelligence Score (CDIS)
SECTION 13.4
PEDIATRIC INOTROPE & VASOACTIVE MANAGEMENT SOP
Clinical Positioning
Vasoactive therapies are viewed as:
Adaptive Hemodynamic Support Tools
rather than simple blood pressure agents.
Primary Objectives
Preserve cardiac output
Preserve cerebral perfusion
Preserve coronary perfusion
Preserve endothelial adaptation
Support myocardial recovery
Monitoring Domains
Lactate
NIRS
Cardiac output
NCRS
ANMS
EII
Vasoactive Burden Classification
Green
Minimal support
Yellow
Moderate support
Orange
High support
Red
Escalating support requirement
SECTION 13.5
LOW CARDIAC OUTPUT PHARMACOLOGY PATHWAY
Objectives
Restore:
Oxygen delivery
Organ perfusion
Recovery reserve
Monitoring Variables
Lactate clearance
Mixed venous oxygen saturation
Perfusion trends
NCRS
Escalation Triggers
Persistent lactate elevation
Declining NIRS
Rising vasoactive burden
SECTION 13.6
ANTIARRHYTHMIC THERAPY INTELLIGENCE PROGRAM
Clinical Positioning
Antiarrhythmic therapies influence:
Rhythm stability
Perfusion
Neurodevelopment
Recovery progression
Therapeutic Domains
Rate Control
Rhythm Control
Electrical Stabilization
Recovery Preservation
Monitoring Variables
Rhythm burden
Hemodynamics
NECIS
Recovery trajectory
SECTION 13.7
ANTIARRHYTHMIC ADAPTATION SURVEILLANCE
Purpose
Detect therapy-associated adaptation failure.
Monitoring Domains
Conduction abnormalities
Ventricular dysfunction
Recovery delay
Developmental burden
Output
Electropharmacology Adaptation Score (EPAS)
SECTION 13.8
ANTICOAGULATION & ANTITHROMBOTIC MANAGEMENT FRAMEWORK
High-Risk Populations
ECMO
VAD
Fontan physiology
Cardiac transplantation
Central venous thrombosis
Strategic Objectives
Prevent thrombosis
Prevent hemorrhage
Preserve perfusion
Preserve endothelial function
Surveillance Variables
Coagulation parameters
Platelet count
Thrombotic burden
Bleeding burden
EII
Output
Hemostatic Adaptation Score (HAS)
SECTION 13.9
POSTOPERATIVE HEMOSTASIS INTELLIGENCE PROGRAM
Clinical Positioning
Postoperative coagulation is viewed as:
Dynamic Endothelial-Hemostatic Adaptation
Monitoring Domains
Clot formation
Clot stability
Endothelial integrity
Recovery progression
Escalation Triggers
Excessive bleeding
Progressive thrombosis
EII decline >15%
SECTION 13.10
IMMUNOSUPPRESSION INTELLIGENCE PROGRAM
Applicable Population
Cardiac transplant recipients
Strategic Objective
Maintain balance between:
Rejection prevention
and
Immune competence preservation
Monitoring Domains
Drug exposure
Infection burden
T-STRI
ANMS
Recovery trajectory
Output
Immunologic Adaptation Index (IAI)
SECTION 13.11
DRUG–DEVELOPMENT INTERACTION SURVEILLANCE SYSTEM
Purpose
Monitor medication effects on:
Brain development
Growth
Endocrine adaptation
Recovery biology
Functional progression
Risk Categories
Green
Minimal developmental burden
Yellow
Moderate developmental surveillance required
Orange
Potential developmental impact
Red
High developmental concern
SECTION 13.12
CARDIOVASCULAR PHARMACOLOGY ANMS INTEGRATION
Neuroimmune Domain
Monitor:
Inflammatory response
Infection risk
Neurocardiac Domain
Monitor:
Contractility
Perfusion
Rhythm stability
Neurovascular Domain
Monitor:
Endothelial adaptation
EII
Neurometabolic Domain
Monitor:
Lactate
Energy utilization
Neuroendocrine Domain
Monitor:
Stress adaptation
Recovery reserve
SECTION 13.13
PHARMACOLOGY ESCALATION MATRIX
Level 1
Enhanced Monitoring
Triggers:
New medication initiation
Dose adjustments
Level 2
Focused Review
Triggers:
Recovery delay
Hemodynamic instability
Developmental concerns
Level 3
Multidisciplinary Pharmacology Review
Triggers:
Polypharmacy burden
Organ dysfunction
Drug toxicity concerns
Level 4
Critical Pharmacology Intervention
Triggers:
Severe toxicity
Life-threatening instability
Progressive ANMS decline
SECTION 13.14
RHENOVA RECOVERY PHARMACOLOGY PROGRAM
Strategic Objective
Transition from rescue-focused pharmacology to recovery-focused pharmacology.
Recovery Targets
Myocardial recovery
Endothelial recovery
Neurodevelopmental recovery
Functional recovery
Growth recovery
Monitoring
CRIS
CRRI
ANMS
NCRS
EII
SECTION 13.15
PHARMACOLOGY SUCCESS ENDPOINTS
Clinical
Stable cardiovascular function
Reduced adverse drug events
Successful therapy de-escalation
Functional
Improved exercise tolerance
Improved rehabilitation participation
Preserved developmental progression
Biological Intelligence
ANMS >80
NCRS >80
EII >80
CRIS >80
CPAI optimized
Sustained adaptive recovery
PAGE 13 COMPLETION
Next Page (Page 14):